In between summer holidays and finishing/starting projects I have been working with several talented interns through Queen Mary University of London micro-internship program.
Anika Soni has been covering therapeutics being developed for neuroinflammation in AD, and this overview will be interesting for anyone working in the space.
In Alzheimer’s disease (AD) therapeutic reviews and pipeline analyses, neuroinflammation is
increasingly discussed alongside established approaches targeting amyloid and tau. However,
describing neuroinflammation as a single therapeutic approach can obscure an important part of
the field: there is no single “neuroinflammation target”.
The biology is considerably more nuanced, with therapeutic strategies approaching
neuroinflammation at different points in the disease process. Broadly, these approaches can be
considered across four areas: enhancing protective microglial function, blocking microglial
inflammatory signalling, removing upstream pathological triggers, and reprogramming the
neuroimmune system. The infographic maps these approaches and the current development
landscape.
This distinction matters because each approach reflects a different hypothesis about the role of
neuroinflammation in AD. Some strategies aim to shift microglia towards more protective functions,
while others seek to suppress inflammatory pathways, prevent pathological signals from initiating
microglial activation, or recalibrate the wider neuroimmune environment. The intended outcomes
therefore also differ, from improving debris clearance and neuronal support to reducing
neurotoxicity and restoring long-term immune homeostasis.
However, the breadth of the landscape should not be confused with clinical validation. Many
approaches remain in preclinical or early clinical development, and important challenges remain
around biological complexity, patient selection, and demonstrating that modulating a particular
mechanism can translate into clinically meaningful benefit.
This makes clinical evidence particularly important. Biomarkers may help identify patients with
relevant neuroinflammatory biology and support target engagement, while clinical data will be
needed to determine which mechanisms should be prioritised and which are unlikely to deliver
tangible benefit.
The potential opportunity is significant. Successful approaches could address aspects of AD
pathophysiology beyond amyloid and tau and expand the range of mechanisms available for
disease modification. The key question is which of these mechanisms can translate from
compelling biology into meaningful disease modification.